Stents no help for patients with narrow kidney arteries



A University of British Columbia geneticist has discovered a gene mutation that can cause the most common eye cancer - uveal melanoma. Catherine Van Raamsdonk, an assistant professor of medical genetics in the UBC Faculty of Medicine and a team of researchers, have discovered a genetic mutation in a gene called GNAQ that could be

Full Post: Cause of uveal melanoma discovered, most common eye cancer

Using stents to open up kidney arteries is commonly done in patients with atherosclerotic renovascular disease, but the procedure provides no benefit, according to a paper being presented at the American Society of Nephrology’s 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania.

Patients with renovascular disease due to atherosclerosis have narrowed blood vessels leading to their kidneys. The condition is relatively common in the general population, and its prevalence increases with age. While revascularization with stents is often performed in an attempt to correct atherosclerotic renovascular disease, there is no reliable evidence that the procedure - which is not without certain risks - improves patients’ kidney function or positively impacts other health outcomes such as blood pressure and survival.

The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial was designed to investigate this issue. Keith Wheatley and his colleagues, including lead nephrologist Phil Kalra, MD, and lead interventional radiologist, Professor Jon Moss, recruited more than 800 patients with atherosclerotic renovascular disease from the United Kingdom and Australasia to the ASTRAL trial. Patients in the study were randomized to undergo revascularization plus medical treatment or medical treatment alone.

The trial’s investigators measured outcomes, including kidney function, blood pressure, major kidney and cardiovascular events, and death, at a span of five years. Unfortunately, the study revealed no clinically worthwhile benefits associated with revascularization on any of the outcomes that were studied.

While investigators hope that large clinical trials such as ASTRAL will show that a potentially promising intervention is effective and improves patient outcomes, it is often the case that the treatment is shown not to have any clinically worthwhile benefits, said Wheatley. “Such ‘negative’ trials are nevertheless very useful and enable treatments that do not work, and which may have risks associated with them, to be eliminated from practice, thereby ensuring patient safety and enabling resources to be better used elsewhere,” he added.

Professor Wheatley and his colleagues hope that the results from the ASTRAL study - the largest randomized trial to date in patients with atherosclerotic renovascular disease - will lead to important changes in the way patients with this disease are treated. The clinical trial’s findings indicate that these individuals should not be subjected to unnecessary revascularization procedures.

http://www.asn-online.org/

Link




A landmark study published in the New England Journal of Medicine (NEJM) demonstrates that use of a specially-designed machine to store kidneys for transplantation offers significant benefits in kidney survival and function when compared to those stored in a traditional “ice box”, or cold storage. Unlike the icebox, the LifePort(R) Kidney Transporter monitors the temperature

Full Post: Specialized kidney transporter improves transplant results



Type 2 diabetics treated with low-dose aspirin did not have a significantly lower incidence of atherosclerotic events than those who received placebo in this primary prevention trial of low-dose aspirin, according to research presented at the American Heart Association’s Scientific Sessions 2008. However, sub-group analyses showed a significant reduction with aspirin in both atherosclerotic events

Full Post: Large trial on low-dose aspirin in diabetics



There are more than 76,000 end-stage renal disease patients waiting for one of the 17,000 kidneys transplanted each year, making a host rejection an unacceptable waste. Kidney transplantation is the preferred treatment for patients with end-stage renal disease. As the demand for organs exceeds the supply, blood group (ABO)-incompatible kidney transplantations have gained much importance

Full Post: Humoral immunity in kidney transplantation



Patients receiving drug eluting stents (DES) - stents coated with medication to prevent narrowing of the artery - as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJ. Mortality in the first 30 days for people with drug

Full Post: Drug eluting stents provide better outcomes that bare metal stents in angioplasty



Individuals who are obese face certain risks when donating their kidneys, but their kidney function remains strong one year later, according to a paper being presented at the American Society of Nephrology’s 41st Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania. As the waiting list for kidney transplants grows, transplant centers are working to facilitate

Full Post: Health complications for obese kidney donors